The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Ibrutinib/Rituximab for CLL/SLL

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we'll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer